Psilocybin depression study ends early, but data still sheds light
NCT ID NCT04353921
First seen May 07, 2026 · Last updated May 07, 2026
Summary
This study was a long-term follow-up of people with major depressive disorder who received a single dose of psilocybin or niacin in an earlier trial. Researchers tracked their depression symptoms through online surveys and phone interviews over one year. The study was terminated early, but the data collected helps understand how long the effects of a single psilocybin dose might last.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Innovative Clinical Research, Inc. (formerly Segal Trials)
Lauderhill, Florida, 33319, United States
Conditions
Explore the condition pages connected to this study.